Andrea Lynn Cox, M.D., Ph.D.

Headshot of Andrea Lynn Cox
  • Director, Medical Scientist Training Program
  • Professor of Medicine
Female

Languages: English, French

Expertise

Acute Viral Hepatitis, HBV/HIV Coinfection, HCV/HIV Coinfection, Hepatitis B (HBV), Hepatitis C (HCV), HIV/AIDS, Infectious Disease ...read more

Research Interests

Viral Immunology; Virus; Protective immunity; Hepatitis C virus; T cell; Vaccine; Immunotherapy ...read more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment

Locations

Johns Hopkins Medicine - Green Spring Station

Appointment Phone: 443-997-1900
10751 Falls Road
Falls Concourse Suite 412
Lutherville, MD 21093
Phone: 410-583-2921 | Fax: 410-583-2654
Johns Hopkins Medicine - Green Spring Station - Google Maps

Background

Dr. Andrea L. Cox is a professor of Internal Medicine at the Johns Hopkins University School of Medicine in the Division of Infectious Diseases and is a member of the Johns Hopkins Kimmel Cancer Center. She holds joint appointments in Oncology and at the Johns Hopkins Bloomberg School of Public Health, in Molecular Microbiology and Immunology. She is an internationally recognized leader in studies of immune responses in immunocompetent and immunocompromised patient populations to viral infections and vaccines against them, including SARS-Co-V-2 (the virus that causes COVID-19), HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). 

Dr. Cox earned her Ph.D. in chemistry from the University of Virginia, where she characterized peptides that drive T cell responses. She then earned her M.D. and completed internal medicine residency and infectious disease fellowship training at Johns Hopkins. 

She leads the largest prospective cohort study of acute HCV infection, designed to enable detailed molecular analysis of HCV transmission, host immune responses, and virus sequence evolution. She co-led the first prophylactic HCV vaccine trial in individuals at risk of HCV infection. She leads a multidisciplinary international team investigating HCV-specific immune responses to improve vaccine development against HCV, is the lead immunologist on a clinical trial of HBV vaccines in people living with HIV,  and co-leads a large team investigating immune responses to COVID-19 infection and vaccines. In addition to her research on viral infections and vaccines, Dr. Cox is actively involved in clinical care of patients with HCV, HIV, and HBV infections.

Dr. Cox serves as the director of the Medical Scientist Training Program. A teacher, advisor, and mentor of physician-scientists and scientists, Dr. Cox mentors Ph.D. students in the Johns Hopkins Cellular and Molecular Medicine, Molecular Microbiology and Immunology, and the Immunology graduate training programs. 

...read more

Titles

  • Director, Medical Scientist Training Program
  • Professor of Medicine
  • Professor of Oncology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; Johns Hopkins University School of Medicine (1998)

Residencies

  • Infectious Diseases; Johns Hopkins University School of Medicine (2000)

Fellowships

  • Infectious Diseases; Johns Hopkins University School of Medicine (2003)

Board Certifications

  • American Board of Internal Medicine (Infectious Disease) (2004)

Research & Publications

Research Summary

Dr. Cox’s laboratory investigates the human immune response to viral infections and vaccines against them, particularly hepatitis C virus (HCV), SARS-CoV-2 (the virus that causes COVID-19), hepatitis B virus (HBV), and HIV.  Her laboratory studies mechanisms through which these infections stimulate and evade immune responses and HCV vaccine development. She is the co-director of the Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2, investigating immune responses to SARS-CoV-2 that are protective versus pathogenic and immune responses to COVID-19 vaccines in immunocompromised and healthy people. She was the principal investigator on the first prophylactic HCV vaccine trial ever implemented in an at-risk population and is the lead immunologist on a trial of HBV vaccines in HIV infected patients.  She heads a team of international investigators dedicated to creating a vaccine to protect against chronic HCV infection.

 

Lab

Lab Website: Andrea Cox Lab

Clinical Trial Keywords

HCV, HBV, COVID-19, HIV, SARS-CoV-2, viruses

Clinical Trials

Dr. Cox has been a coinvestigator in clinical trials to cure HCV and HBV and of vaccines against HBV and HCV.  

Selected Publications

Page K, Melia MT, Veenhuis RT, Winter M, Rousseau KE, Massaccesi G, Osburn WO, Forman M, Thomas E, Thornton K, Wagner K, Vassilev V, Lin L, Lum PJ, Giudice LC, Stein E, Asher A, Chang S, Gorman R, Ghany MG, Liang TJ, Wierzbicki MR, Scarselli E, Nicosia A, Folgori A, Capone S, Cox AL. Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. N Engl J Med. 2021 Feb 11;384(6):541-549

Thompson EA, Cascino K, Ordonez AA, Zhou W, Vaghasia A, Hamacher-Brady A, Brady NR, Sun IH, Wang R, Rosenberg AZ, Delannoy M, Rothman R, Fenstermacher K, Sauer L, Shaw-Saliba K, Bloch EM, Redd AD, Tobian AAR, Horton M, Smith K, Pekosz A, D'Alessio FR, Yegnasubramanian S, Ji H, Powell JD*, Cox AL*. Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. Cell Rep. 2021 Mar 16;34(11):108863. *co-corresponding authors

Karaba AH, Zhou W, Hsieh LL, Figueroa A, Massaccesi G, Rothman RE, Fenstermacher KZJ, Sauer L, Shaw-Saliba K, Blair PW, Robinson ML, Leung S, Wesson R, Alachkar N, El-Diwany R, Ji H, Cox AL. Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology. Clin Infect Dis. 2022 Jan 29;74(2):254-262

Thompson EA, Ngecu W, Stoddart L, Johnston TS, Chang A, Cascino K, Alejo JL, Abedon AT, Samaha H, Rouphael N, Tobian AA, Segev DL, Werbel WA, Karaba AH, Blankson JN, Cox AL. Heterologous versus homologous boosting elicits qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients. JCI Insight. 2023 May 22;8(10):e168470

Veenhuis RT, Freeman ZT, Korleski J, Cohen LK, Massaccesi G, Tomasi A, Boesch AW, Ackerman ME, Margolick JB, Blankson JN, Chattergoon MA, Cox AL. HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells. J Clin Invest. 2017 Dec 1;127(12):4352-4364

Academic Affiliations & Courses

Graduate Program Affiliation

 

Activities & Honors

Honors

  • Member of The American Society for Clinical Investigation, 2013
  • Career Development Award, Sidney Kimmel Comprehensive Cancer Center
  • Fellow of the Infectious Disease Society of America, Infectious Disease Society of America
  • The Professors Award for Excellence in Teaching, The Johns Hopkins University School of Medicine

Memberships

  • The Infectious Disease Society of America

    An organization that represents physicians, scientists and other health care professionals who specialize in infectious diseases.

  • The American Association for the Study of Liver Disease

    An organization of scientists and health care professionals committed to preventing and curing liver disease

  • The American Association of Immunologists

    An association of scientists dedicated to advancing the knowledge of immunology and its related disciplines

  • The American Society for Clinical Investigation
Is this you? Edit Profile
back to top button